Michael Torok Takes His Place on the Board
Amarin Corporation plc (NASDAQ:AMRN) has made a significant move with the announcement that Michael Torok, the Co-Founder and Managing Director of JEC Capital Partners, will be joining their Board of Directors immediately. This addition is expected to bring valuable financial expertise and strategic insight to the boardroom.
Odysseas Kostas, MD, the Chairman of the Board, expressed his enthusiasm about Michael’s joining, stating, “On behalf of the board, I welcome Michael. His financial expertise, experience on other boards, and his shared priority to maximize shareholder value make him a beneficial addition to the board at this time.”
Welcoming a New Perspective
Michael Torok is eager to start his journey with Amarin, aiming to collaborate with fellow directors and the management team. He stated, “I am eager to join the board and begin working with fellow directors and the senior management team to deliver on our shared interest to maximize value.” His commitment to transparency and collaboration could bolster the board’s intentions for all shareholders.
Deep Industry Experience
Michael brings a wealth of experience to his new role. As the Co-Founder and Managing Director of JEC Capital Partners, he has a notable background in investment management. He has served on various boards of public and private companies across different industries, contributing strategic insights and oversight in audit, compensation, governance, and other board committees.
Previous Accomplishments
Before his tenure at JEC Capital Partners, Mr. Torok held the position of Chief Financial Officer at Integrated Dynamics Engineering, where he played a pivotal role in its acquisition by Aalberts Industries. His earlier career at PricewaterhouseCoopers LLP equipped him with extensive experience in financial services, further enhancing his qualifications.
About Amarin Corporation
Amarin Corporation is at the forefront of innovative approaches in cardiovascular disease management. With its headquarters in Bridgewater, New Jersey, and additional locations in Dublin, Ireland, and Zug, Switzerland, Amarin is committed to advancing treatments that address persistent cardiovascular risks not sufficiently managed by traditional therapies.
The company continually seeks to enhance the scientific understanding of cardiovascular conditions, focusing on maximizing shareholder value and improving patient outcomes. This dedication places Amarin on a path of significant impact in the pharmaceutical landscape.
Staying Informed on Amarin
Amarin encourages its investors and the wider public to stay engaged with the company’s developments through its official channels. These include investor presentations, Securities and Exchange Commission filings, and periodic updates on their progress. Investors can find comprehensive materials that provide insights into Amarin's strategies, recent developments, and future direction.
Contacting Amarin for Inquiries
For any inquiries relating to investor relations or media engagements, Mark Marmur is the primary contact at Amarin Corporation. He can address any questions regarding the company's activities and objectives. Below are the contact details for inquiries:
Email: PR@amarincorp.com
Email: Investor.relations@amarincorp.com
Frequently Asked Questions
1. What new role has Michael Torok taken on at Amarin?
Michael Torok has been appointed to the Board of Directors of Amarin Corporation.
2. What experience does Michael Torok bring to the board?
Michael has extensive experience in investment management and has served on multiple corporate boards across various industries.
3. How does Amarin Corporation contribute to cardiovascular health?
Amarin focuses on advancing treatments for cardiovascular disease, aiming to enhance patient outcomes beyond traditional therapies.
4. Where are Amarin's headquarters located?
Amarin Corporation’s headquarters are in Bridgewater, New Jersey, with additional offices in Ireland and Switzerland.
5. How can interested parties learn more about Amarin?
Interested individuals can visit Amarin's investor relations website and company website to stay updated on developments.
